These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30284688)

  • 1. Retrospective Cohort Analysis of the Reduced Burden of Hypoglycemia Associated with Dipeptidyl Peptidase-4 Inhibitor Use in Patients with Type 2 Diabetes Mellitus.
    Tang Y; Liu J; Hannachi H; Engel SS; Ganz ML; Rajpathak S
    Diabetes Ther; 2018 Dec; 9(6):2259-2270. PubMed ID: 30284688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
    Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
    Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
    Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
    Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
    Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
    Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Heterogeneity and Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and DPP-4 Inhibitors: Population-Based Cohort Study.
    Dimakos J; Cui Y; Platt RW; Renoux C; Filion KB; Douros A
    Clin Pharmacol Ther; 2023 Sep; 114(3):712-720. PubMed ID: 37326010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease.
    Baksh SN; Segal JB; McAdams-DeMarco M; Kalyani RR; Alexander GC; Ehrhardt S
    PLoS One; 2020; 15(10):e0240141. PubMed ID: 33057387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma development among type 2 diabetes patients.
    Li PF; Chung CH; Liu JS; Lu CH; Su SC; Kuo FC; Ho LJ; Chen KC; Su YT; Chu NF; Lee CH; Hsieh CH; Hung YJ; Lin FH; Chien WC; Liang YJ
    Ther Adv Respir Dis; 2022; 16():17534666221135320. PubMed ID: 36448591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients With Prediabetes or Diabetes After Cardiac Surgery.
    Clark L; Weeda E; Griffin ML; Jones LA; Haney J
    J Pharm Pract; 2021 Apr; 34(2):259-264. PubMed ID: 31409190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
    Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
    BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review.
    Ruan Z; Zou H; Lei Q; Ung COL; Shi H; Hu H
    Expert Rev Pharmacoecon Outcomes Res; 2022 Jun; 22(4):555-574. PubMed ID: 35152812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Kim S; Han SJ; Kim DJ; Lee KW; Kim HJ
    J Diabetes Res; 2018; 2018():5246976. PubMed ID: 29850606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of costs and outcomes of dapagliflozin with other glucose-lowering therapy classes added to metformin using a short-term cost-effectiveness model in the US setting.
    Chakravarty A; Rastogi M; Dhankhar P; Bell KF
    J Med Econ; 2018 May; 21(5):497-509. PubMed ID: 29376760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors.
    Seong JM; Kim JJ; Kim HJ; Sohn HS
    Front Pharmacol; 2021; 12():689885. PubMed ID: 34650428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study.
    Kim YG; Jeon JY; Kim HJ; Kim DJ; Lee KW; Moon SY; Han SJ
    J Clin Med; 2018 Dec; 8(1):. PubMed ID: 30597861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 19. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients.
    Yang CY; Lin WA; Su PF; Li LJ; Yang CT; Ou HT; Kuo S
    Clin Pharmacol Ther; 2021 Mar; 109(3):772-781. PubMed ID: 32978779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dipeptidyl peptidase-4 inhibitor on the progression of coronary artery disease evaluated by computed tomography in patients receiving insulin therapy for type 2 diabetes mellitus.
    Choi Y; Ko SH; Chang K; Yoo KD; Ihm SH
    J Diabetes; 2023 Nov; 15(11):944-954. PubMed ID: 37528628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.